Bioinformatics analysis on several online databases confirms that SHMT1 and SHMT2 may be potential therapeutic and prognostic biomarkers in patients with RCC and SP3 may be important a target for RCC treatment (Situ et al., 2023). This evidence concerns the gene SHMT1 and renal cell carcinoma.